Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension - results of the TOPIC (Trial Of Physiotens In Combination) Study

Waters J; Ashford J; Jäger B; Verboom CN; Wonnacott S

Waters J et al.

Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension - results of the TOPIC (Trial Of Physiotens In Combination) Study

Journal of Clinical and Basic Cardiology 1999; 2 (2): 219-224

PDF Summary Figures

Figure

Maximize View	TOPIC-Studie - Design Figure 1: Study plan for TOPIC. A = placebo run-in phase (4 weeks; n = 792). B = open-label monotherapy phase (8 weeks; n = 678; moxonidine 200 mcg/day for 4 weeks, then 200 or 400 mcg/day as required). C = moxonidine monotherapy (4 weeks; n = 303; moxonidine 200 or 400 mcg/day as required for 4 weeks). D, E, F = combination therapy (4 weeks; moxonidine [400 mcg/day] plus other agent as specified below). D = moxonidine plus amlodipine (5 mg/day) (n = 87). E = moxonidine plus enalapril (10 mg/day) (n = 88). F = moxonidine plus hydrochlorothiazide (12.5 mg/day) (n = 97). Keywords: Amlodipin, amlodipine, Design, Design, Hydrochlorothiazid, hydrochlorothiazide, Moxonidin, moxonidine, Schema, Studie, study, TOPIC, TOPIC